Expanded Access Program of PEGASYS® (Peg interferon alpha-2a (40 KD)) in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
Phase of Trial: Phase IV
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Expanded access; Therapeutic Use
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 08 Feb 2017 Last checked against ClinicalTrials.gov record.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.